Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 2;11(3):01079-2024.
doi: 10.1183/23120541.01079-2024. eCollection 2025 May.

Dual Bronchodilators in Bronchiectasis Study: a randomised controlled trial

Nina Wilson  1 , Miranda Morton  2 , Tara Homer  3 , Ann Breeze Konkoth  1 , Richard Joyce  2 , Anneka Kershaw  2 , Hazel Wilde  2 , Alison Liddle  2 , James Wason  1 , Laura Ternent  3 , Maria Allen  4 , Robert Lord  5 , John Steer  6 , Graham Devereux  7 , James D Chalmers  8 , Adam T Hill  9 , Charles S Haworth  10 , John R Hurst  11 , Anthony De Soyza  4   12
Affiliations

Dual Bronchodilators in Bronchiectasis Study: a randomised controlled trial

Nina Wilson et al. ERJ Open Res. .

Abstract

This study comparing exacerbations rates for dual bronchodilator therapy, triple therapy and placebo in bronchiectasis cannot provide definitive evidence. However, results suggest signs of of efficacy: a larger trial may provide valuable clinical evidence. https://bit.ly/4fuuHHX.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: N. Wilson, M. Morton and A.B. Konkoth report receiving grants from the National Institute of Health and Care Research (NIHR). J. Wason reports being funded by a NIHR Research Professorship (NIHR301614), being a panel member on NIHR Healthcare Technology Assessment Funding Committee (2020–2024) selection panel Chair for NIHR Undergraduate Internship scheme (2024) and receiving GSK funding for a PhD studentship. L. Ternent reports receiving grants from the NIHR. J. Steer reports received grants from Chiesi, personal payments and support for attending meetings/travel from Astra Zeneca, and personal payments from UK Cardiopulmonary Taskforce. G. Devereux reports receiving grants from the NIHR. J.D. Chalmers reports receiving grants from NIHR, AstraZeneca, Boehringer Ingelheim, GSK, Zambon, Insmed and Gilead; receiving personal fees from AstraZeneca, Boehringer Ingelheim, GSK, Zambon, Insmed, Novartis and Cheisi; and is an associate editor of this journal. A.T. Hill reports being Chair of the British Thoracic Society Standards of Care Committee. C.S. Haworth reports receiving grants from NIHR; receiving consulting fees from 30 Technology, Astra Zeneca, CSL Behring, Chiesi, Infex, Insmed, Janssen, LifeArc, Meiji, Mylan, Pneumagen, Shionogi, Vertex and Zambon; receiving fees for advisory and educational work from Chiesi, Insmed, Mylan and Zambon; and holding stock/stock option in Pneumagen. J.R. Hurst reports receiving grants from AstraZeneca, and receiving fees for advisory and educational work from AstraZeneca, Boehringer Ingleheim, Chiesi, GSK, Novartis and Sanofi. A. De Soyza reports receiving grant awards from NIHR, and grant support from Astra Zeneca, Bayer, Gilead, Chiesi, Pfizer and GSK; and receiving speaker fees for bureau/advisory committee work from Astra Zeneca, Bayer, Gilead, Chiesi, Pfizer, GSK, 30 T Pharmaceuticals and Insmed. All other authors have nothing to disclose.

Figures

FIGURE 1
FIGURE 1
a) Histograms of number of bronchiectasis exacerbations requiring antibiotics during the trial per treatment group. Note that for the three participants who withdrew early, their number of episodes has not been adjusted for their shorter time in study. b) Comparison of the number of bronchiectasis exacerbations requiring antibiotics during the trial between treatment groups (n=32). The results are presented as incident rate ratios (IRRs) with a 95% confidence interval. These estimates are from fitting an exploratory negative binomial regression model adjusted for the stratification factors of Bronchiectasis Severity Index score and baseline inhaled corticosteroids drug therapy. The time at risk was considered to be the time not spent in exacerbation (hence, whilst a participant was experiencing an exacerbation they were not included as at risk of another). c) Kaplan–Meier estimates of survivor functions by treatment groups.
See this image and copyright information in PMC

References

    1. BTS Bronchiectasis in Adults Guideline Development Group . British thoracic society guideline for bronchiectasis in adults. Thorax 2019; 74: Suppl. 1: 1–69. doi:10.1136/thoraxjnl-2018-212463 - DOI - PubMed
    1. Polverino E, Goeminne PC, McDonnell MJ, et al. , European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017; 50: 1700629. doi:10.1183/13993003.00629-2017 - DOI - PubMed
    1. Welsh EJ, Evans DJ, Fowler SJ, et al. . Interventions for bronchiectasis: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev 2015; 2015: Cd010337. doi:10.1002/14651858.CD010337.pub2 - DOI - PMC - PubMed
    1. Hill AT, Pasteur M, Cornford C, et al. . Primary care summary of the British Thoracic Society Guideline on the management of non-cystic fibrosis bronchiectasis. Prim Care Respir J 2011; 20: 135–140. doi:10.4104/pcrj.2011.00007 - DOI - PMC - PubMed
    1. Hill AT, Barker AF, Bolser DC, et al. . Treating cough due to non-CF and CF bronchiectasis with nonpharmacological airway clearance: CHEST expert panel report. Chest 2018; 153: 986–993. doi:10.1016/j.chest.2018.01.014 - DOI - PMC - PubMed

LinkOut - more resources